Skip to main content


Media Contacts:


Emmanuella Dekonor
Mobile: +44 7920500496 

United States

Polina Miklush
Mobile: +1 908 608 7170

Asia Pacific

Hamish Walsh
Palin Communications
Mobile: 0422 424 338

Seqirus news releases

Seqirus news releases

Seqirus and U.S. Government Renew Multi-Year Agreement for Influenza Pandemic Preparedness and Response

25 Feb 2022

• Renewal reaffirms longstanding, public-private partnership between Seqirus and the Biomedical Advanced Research and Development Authority (BARDA) to strengthen preparedness and rapid response capabilities for influenza pandemics
• Agreement includes provision for Seqirus to provide BARDA with supply of AUDENZ, the first-ever FDA-approved adjuvanted, cell-based pandemic influenza vaccine, which was developed in partnership with BARDA

Seqirus, a Business of CSL Limited, Announces New Facility Supporting Research & Development of Leading-Edge Influenza Vaccine Technology

07 Feb 2022

New facility in Waltham, Massachusetts, will support CSL’s growing R&D portfolio, including the self-amplifying mRNA technology platform, the next generation of mRNA vaccine technology, for seasonal and pandemic influenza vaccines.

EU Flu Day 2021 – Seqirus joins experts’ calls to boost vaccine uptake ahead of a second influenza season during the COVID-19 pandemic

14 Oct 2021

• Expert modelling points to a more severe influenza season than in previous years.1
• The lifting of restrictions to reduce COVID-19 transmission may leave vulnerable people – with reduced immunity - at greater risk from influenza.1
• Co-administration of the seasonal influenza vaccine with the COVID-19 booster may not only protect vulnerable populations, it could also relieve the burden on healthcare systems.
• A panel of leading international experts discuss the challenges of the oncoming influenza season at this year’s EU Flu Day, led by Vaccines Europe and supported by Seqirus.

Seqirus Awarded U.S. Government Contract to Develop Two Pandemic Influenza Vaccines

04 Oct 2021

• Seqirus will develop and evaluate two influenza A(H2Nx) virus vaccine candidates in support of U.S. government pandemic preparedness objectives
• Company will utilize its combination of cell-based and adjuvanted influenza vaccine technologies, as well as its next-generation self-amplifying mRNA platform
• Multi-year contract with Biomedical Advanced Research and Development Authority (BARDA) builds on longstanding, successful public-private partnership to provide rapid vaccine manufacturing response in an influenza pandemic

Seqirus Announces Investment in Next-Generation Influenza Vaccine Technology, Self-Amplifying Messenger RNA (sa-mRNA)

19 Aug 2021

• Appoints Roberta Duncan as new program lead to drive technology advancement
• Accelerates development of sa-mRNA vaccine candidates for seasonal and pandemic influenza

Seqirus Begins Shipping Portfolio of Innovative Vaccines for the 2021/22 U.S. Influenza Season

27 Jul 2021

The company is prepared to meet the record levels of demand seen during the 2020/21 influenza season amidst the ongoing COVID-19 pandemic.

Seqirus strengthens U.K. influenza vaccine response as high-speed fill and finish facility begins rolling 30 million doses in Liverpool

01 Jun 2021

First doses of Seqirus’s enhanced influenza vaccine, destined for the U.K., come off a new high-speed fill-and-finish line in Liverpool.

CSL Named as One of the World’s Best Employers

29 Oct 2020

Forbes Recognizes Global Biotechnology Leader for Fourth Straight Year

This EU Flu Day, Seqirus confirms record number of influenza vaccines delivered across Europe to meet increased demand

14 Oct 2020

The first annual EU Flu Day was launched today, 14 October 2020. Marking the occasion, Seqirus, a global leader in influenza prevention, announced that it has delivered shipments of influenza vaccines on schedule, across Europe

CSL to manufacture and supply University of Queensland and Oxford University vaccine candidates for Australia

07 Sep 2020

CSL Limited (ASX:CSL) today announced it has signed a Heads of Agreement (HoA) with the Australian Government for the supply of 51 million doses of the University of Queensland’s (UQ) COVID-19 vaccine candidate (V451), and a separate HoA with AstraZeneca to manufacture the Oxford University candidate (AZD1222), should clinical trials of both prove successful.

First adjuvanted quadrivalent influenza vaccine receives EU approval

08 Jun 2020

This news release is intended for medical, pharmaceutical industry and business media